Big Pharma vs Big Pharma in court battles over biosimilar drugs

ZURICH (Reuters) - The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals' complex biological medicines.